Evidence map›Paper›PMID 41537917›Full record

ArticleJournal of gastrointestinal cancer2026

The Methylation Level of Circulating Tumor DNA Predicts Prognosis for Stage I-III Colorectal Cancer.

Takahiro Irie, Kiichi Sugimoto, Hirotaka Momose, Yuki Tsuchiya, Ryoichi Tsukamoto, Kumpei Honjo, Hisashi Ro, Shun Ishiyama, Makoto Takahashi, Thomas Pisanic and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of gastrointestinal cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Takahiro IrieDepartment of Coloproctological Surgery, Juntendo University Faculty of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
Kiichi SugimotoDepartment of Coloproctological Surgery, Juntendo University Faculty of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan. ksugimo@juntendo.ac.jp.
Hirotaka MomoseDepartment of Coloproctological Surgery, Juntendo University Faculty of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
Yuki TsuchiyaDepartment of Coloproctological Surgery, Juntendo University Faculty of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
Ryoichi TsukamotoDepartment of Coloproctological Surgery, Juntendo University Faculty of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
Kumpei HonjoDepartment of Coloproctological Surgery, Juntendo University Faculty of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
Hisashi RoDepartment of Coloproctological Surgery, Juntendo University Faculty of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
Shun IshiyamaDepartment of Coloproctological Surgery, Juntendo University Faculty of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
Makoto TakahashiDepartment of Coloproctological Surgery, Juntendo University Faculty of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
Thomas PisanicInstitute for NanoBioTechnology, Johns Hopkins University, 3400 North Charles, Shaffer Hall 103, Baltimore, MD, 21218, USA.
Akio SaiuraDepartment of Hepatobiliary-Pancreatic Surgery, Faculty of Medicine, Juntendo University, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.
Kazuhiro SakamotoDepartment of Coloproctological Surgery, Juntendo University Faculty of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan.

Funding

Grant-in-aid for Scientific Research from the Japanese Society for the Promotion of Science 16K19957
6 · The paper itself

Abstract

purposeColorectal cancer (CRC) remains a significant health burden worldwide. Although some clinicopathological factors have been identified in stage I-III CRCs, there is a need to identify new prognostic factors. This study aimed to investigate the clinical utility of circulating tumor DNA (ctDNA) methylation analysis in predicting the prognosis of stage I-III CRCs.

methodsMethylation analyses were performed on 273 preoperative plasma samples from CRC patients who underwent surgery at Juntendo University Hospital between 2011 and 2019. The methylation levels of three tumor suppressor genes (CHFR, SOX11 and CDO1) were analyzed as relative methylation value (RMV).

resultsThere were no significant differences in the methylation levels of each gene among different stages of CRC. However, multivariate analysis revealed that the methylation level of SOX11 was an independent prognostic factor (Hazard ratio (HR) = 2.37 (1.20-4.67), p = 0.01). Subgroup analysis of stage III CRC also showed methylation levels of SOX11 and CDO1 were independent prognostic factors (HR = 2.66 (1.16-6.07), p = 0.02 and HR = 2.51 (1.06-5.94), p = 0.04, respectively). In cases with high CHFR and CDO1-RMV, the use of postoperative adjuvant chemotherapy (POAC) was related to significantly higher RFS (p = 0.006 and p = 0.001, respectively). However, no significant effect of POAC was seen in high SOX11-RMV cases (p = 0.24).

conclusionsThis study demonstrated the clinical utility of ctDNA methylation analysis for predicting prognosis in stage I-III CRCs. Furthermore, the ctDNA methylation status might be a biomarker for identifying the patients who can benefit from POAC.

Indexed as

Biomarkers, TumorCirculating Tumor DNAColorectal NeoplasmsDNA MethylationAdultAgedAged, 80 and overCysteine DioxygenaseFemaleHumansMaleMiddle AgedNeoplasm StagingPrognosisBiomarkers, TumorCDO1 protein, humanCirculating Tumor DNACysteine DioxygenaseCirculating tumor DNA (ctDNA)Colorectal cancerDNA methylationLiquid biopsyPostoperative adjuvant chemotherapyPrognostic factor

Identifiers

PMID41537917

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.